Sinovac Biotech Ltd Quick Ratio (SVA) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Sinovac Biotech Ltd  (NASDAQ: SVA)

Sinovac Biotech Ltd's Quick Ratio

SVA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 4.31 above company average Quick Ratio.

Within Major Pharmaceutical Preparations industry 213 other companies have achieved higher Quick Ratio than Sinovac Biotech Ltd in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 441 to 1006.

Explain Quick Ratio?
How much Cash & cash equivalents SVA´s has?
What are SVA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SVA Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 28.48 % 6.09 % 6.09 % 6.09 % -31.12 %
Y / Y Cash & cash equivalent Change 141.82 % -35.01 % -35.01 % -35.01 % -77.46 %
Quick Ratio MRQ 4.31 4.31 4.31 4.31 2.29
SVA's Total Ranking # 1006 # 441 # # #
Seq. Current Liabilities Change 0 % 0 % 0 % 28.48 % -17.42 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % 141.82 % -73.12 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 214
Healthcare Sector # 355
Overall Market # 1006


Quick Ratio Statistics
High Average Low
10.37 3.59 0.96
0   (Dec 31 2015)




Financial Statements
Sinovac Biotech Ltd's Current Liabilities $ 1,540 Millions Visit SVA's Balance sheet
Sinovac Biotech Ltd's Cash & cash equivalent $ 6,640 Millions Visit SVA's Balance sheet
Source of SVA's Sales Visit SVA's Sales by Geography


Cumulative Sinovac Biotech Ltd's Quick Ratio

SVA's Quick Ratio for the trailling 12 Months

SVA Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 10.92 % -4.53 % -1.05 % 2.82 % 7.14 %
Y / Y Cash & cash equivalent TTM Growth -20.47 % -47.08 % -40.14 % -33.52 % -27.19 %
Quick Ratio TTM 4.31 3.89 4.58 5.28 6.01
Total Ranking TTM # 3373 # 3141 # # #
Seq. Current Liabilities TTM Growth 5.87 % 1.54 % 1.57 % 1.59 % -8.88 %
Seq. Cash & cash equivalent TTM Growth 17.18 % -13.63 % -11.99 % -10.71 % -22.03 %

Quick ratio ranking by company, industry and sector >> Back to SVA Financial Strength Comparisons >> Go to Compare SVA Quick Ratio to its Competitors

On the trailing twelve months basis SVA Cash & cash equivalent more than doubled by 141.82 % in Q4 2025 year on year, faster than Current Liabilities, this led to increase in in Sinovac Biotech Ltd's Quick Ratio to 4.31, Quick Ratio remained below SVA average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 422 other companies have achieved higher Quick Ratio than Sinovac Biotech Ltd. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 3141 to 3373.

Explain Quick Ratio?
How much Cash & cash equivalents SVA´s has?
What are SVA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 423
Healthcare Sector # 850
Within the Market # 3373


trailing twelve months Quick Ratio Statistics
High Average Low
10.37 4.31 0.99
(Dec 31 2022)   (Dec 31 2016)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Crescent Biopharma Inc   11.85 $ 213.192  Millions$ 17.997  Millions
Equillium Inc   11.78 $ 30.277  Millions$ 2.571  Millions
Pepgen Inc   11.74 $ 148.456  Millions$ 12.646  Millions
Canton Strategic Holdings Inc   11.68 $ 12.007  Millions$ 1.028  Millions
Pliant Therapeutics Inc   11.67 $ 190.944  Millions$ 16.365  Millions
Savara Inc   11.56 $ 235.702  Millions$ 20.396  Millions
Mineralys Therapeutics Inc   11.44 $ 172.921  Millions$ 15.113  Millions
Avalyn Pharma Inc   11.33 $ 154.604  Millions$ 13.647  Millions
Innoviva Inc   11.09 $ 550.941  Millions$ 49.696  Millions
Bicycle Therapeutics Plc  11.02 $ 628.110  Millions$ 56.984  Millions
Ideaya Biosciences Inc   10.93 $ 639.388  Millions$ 58.476  Millions
Aardvark Therapeutics Inc   10.89 $ 110.027  Millions$ 10.107  Millions
First Tracks Biotherapeutics Inc   10.77 $ 311.638  Millions$ 28.943  Millions
Revium Rx.  10.29 $ 5.279  Millions$ 0.513  Millions
Sellas Life Sciences Group Inc   10.25 $ 71.893  Millions$ 7.017  Millions
Ovid Therapeutics Inc   10.16 $ 69.635  Millions$ 6.855  Millions
Praxis Precision Medicines Inc   10.05 $ 599.331  Millions$ 59.661  Millions
Whitehawk Therapeutics Inc   10.03 $ 145.697  Millions$ 14.519  Millions
Edesa Biotech Inc   10.01 $ 10.800  Millions$ 1.079  Millions
Neuphoria Therapeutics Inc   9.99 $ 14.311  Millions$ 1.433  Millions
Onkure Therapeutics Inc   9.97 $ 59.050  Millions$ 5.921  Millions
Immix Biopharma Inc   9.93 $ 100.409  Millions$ 10.111  Millions
Pmv Pharmaceuticals Inc   9.89 $ 112.943  Millions$ 11.415  Millions
Galera Therapeutics Inc   9.88 $ 6.375  Millions$ 0.645  Millions
Olema Pharmaceuticals Inc   9.76 $ 505.437  Millions$ 51.802  Millions
Erasca Inc   9.68 $ 276.075  Millions$ 28.511  Millions
Bioage Labs Inc   9.58 $ 192.920  Millions$ 20.138  Millions
Relmada Therapeutics Inc  9.57 $ 93.006  Millions$ 9.723  Millions
Ataibeckley Inc   9.40 $ 220.651  Millions$ 23.479  Millions
Viking Therapeutics Inc   9.22 $ 705.739  Millions$ 76.530  Millions

Date modified: 2026-09-16T10:47:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.